These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 20098230)

  • 21. Desvenlafaxine: another "me too" drug?
    Sopko MA; Ehret MJ; Grgas M
    Ann Pharmacother; 2008 Oct; 42(10):1439-46. PubMed ID: 18698015
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans.
    Lessard E; Yessine MA; Hamelin BA; Gauvin C; Labbé L; O'Hara G; LeBlanc J; Turgeon J
    J Clin Psychopharmacol; 2001 Apr; 21(2):175-84. PubMed ID: 11270914
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Marked increase of venlafaxine enantiomer concentrations as a consequence of metabolic interactions: a case report.
    Eap CB; Bertel-Laubscher R; Zullino D; Amey M; Baumann P
    Pharmacopsychiatry; 2000 May; 33(3):112-5. PubMed ID: 10855463
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Outliers on the dose-response curve: how to minimize this problem using therapeutic drug monitoring, an underutilized tool in psychiatry.
    Preskorn SH
    J Psychiatr Pract; 2010 May; 16(3):177-82. PubMed ID: 20485106
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The impact of cytochrome P450-2D6 genotype on the use and interpretation of therapeutic drug monitoring in long-stay patients treated with antidepressant and antipsychotic drugs in daily psychiatric practice.
    Mulder H; Herder A; Wilmink FW; Tamminga WJ; Belitser SV; Egberts AC
    Pharmacoepidemiol Drug Saf; 2006 Feb; 15(2):107-14. PubMed ID: 16294366
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Concordance of P450 2D6 (debrisoquine hydroxylase) phenotype and genotype: inability of dextromethorphan metabolic ratio to discriminate reliably heterozygous and homozygous extensive metabolizers.
    Evans WE; Relling MV
    Pharmacogenetics; 1991 Dec; 1(3):143-8. PubMed ID: 1688245
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of low-dose ritonavir (100 mg twice daily) on the activity of cytochrome P450 2D6 in healthy volunteers.
    Aarnoutse RE; Kleinnijenhuis J; Koopmans PP; Touw DJ; Wieling J; Hekster YA; Burger DM
    Clin Pharmacol Ther; 2005 Dec; 78(6):664-74. PubMed ID: 16338282
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Depressive effect of an antidepressant: therapeutic failure of venlafaxine in a case lacking CYP2D6 activity.
    Wijnen PA; Limantoro I; Drent M; Bekers O; Kuijpers PM; Koek GH
    Ann Clin Biochem; 2009 Nov; 46(Pt 6):527-30. PubMed ID: 19822698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of CYP2D6 activity on the disposition and cardiovascular toxicity of the antidepressant agent venlafaxine in humans.
    Lessard E; Yessine MA; Hamelin BA; O'Hara G; LeBlanc J; Turgeon J
    Pharmacogenetics; 1999 Aug; 9(4):435-43. PubMed ID: 10780263
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Alternative venlafaxine kinetics in overdose.
    Langford NJ; Martin U; Ruprah M; Ferner RE
    J Clin Pharm Ther; 2002 Dec; 27(6):465-7. PubMed ID: 12472987
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does tachyphylaxis occur after repeated antidepressant exposure in patients with Bipolar II major depressive episode?
    Amsterdam JD; Shults J
    J Affect Disord; 2009 May; 115(1-2):234-40. PubMed ID: 18694599
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Steady-state concentration of venlafaxine enantiomers: model-based analysis of between-patient variability.
    Gex-Fabry M; Rudaz S; Balant-Gorgia AE; Brachet A; Veuthey JL; Balant LP; Bertschy G
    Eur J Clin Pharmacol; 2002 Aug; 58(5):323-31. PubMed ID: 12185556
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Metabolic ratios of psychotropics as indication of cytochrome P450 2D6/2C19 genotype.
    van der Weide J; van Baalen-Benedek EH; Kootstra-Ros JE
    Ther Drug Monit; 2005 Aug; 27(4):478-83. PubMed ID: 16044105
    [TBL] [Abstract][Full Text] [Related]  

  • 34. No evidence of increased adverse drug reactions in cytochrome P450 CYP2D6 poor metabolizers treated with fluoxetine or nortriptyline.
    Roberts RL; Mulder RT; Joyce PR; Luty SE; Kennedy MA
    Hum Psychopharmacol; 2004 Jan; 19(1):17-23. PubMed ID: 14716707
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rapid and reliable genotyping procedure for detection of alleles with mutations, deletion, or/and duplication of the CYP2D6 gene.
    Arneth B; Shams M; Hiemke C; Härtter S
    Clin Biochem; 2009 Aug; 42(12):1282-90. PubMed ID: 19393232
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A poor metabolizer of both CYP2C19 and CYP2D6 identified by mechanistic pharmacokinetic simulation in a fatal drug poisoning case involving venlafaxine.
    Jornil J; Nielsen TS; Rosendal I; Ahlner J; Zackrisson AL; Boel LW; Brock B
    Forensic Sci Int; 2013 Mar; 226(1-3):e26-31. PubMed ID: 23332809
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phenoconversion of cytochrome P450 2D6: the need for identifying the intermediate metabolizer genotype.
    Berm EJ; Risselada AJ; Mulder H; Hak E; Wilffert B
    J Clin Psychiatry; 2013 Oct; 74(10):1025. PubMed ID: 24229757
    [No Abstract]   [Full Text] [Related]  

  • 38. Effect of venlafaxine versus fluoxetine on metabolism of dextromethorphan, a CYP2D6 probe.
    Amchin J; Ereshefsky L; Zarycranski W; Taylor K; Albano D; Klockowski PM
    J Clin Pharmacol; 2001 Apr; 41(4):443-51. PubMed ID: 11304901
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Fluoxetine and tricyclic antidepressants: clinical tolerance in short-term combined administration].
    Bonin B; Bertschy G; Baumann P; Francois T; Vandel P; Vandel S; Sechter D; Bizouard P
    Encephale; 1996; 22(3):221-7. PubMed ID: 8767051
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CYP2D6 polymorphism and clinical effect of the antidepressant venlafaxine.
    Shams ME; Arneth B; Hiemke C; Dragicevic A; Müller MJ; Kaiser R; Lackner K; Härtter S
    J Clin Pharm Ther; 2006 Oct; 31(5):493-502. PubMed ID: 16958828
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.